The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis
Open accessAbstract
One hundred eighty-four serum samples from patients with ovarian cancer ( n = 109), patients with benign tumors ( n = 19), and healthy donors ( n = 56) were analyzed on strong anion-exchange surfaces using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry technology. Univariate and multivariate statistical analyses applied to protein-profiling data obtained from 140 training serum samples identified three biomarker protein panels. The first panel of five candidate protein biomarkers, termed the screening biomarker panel, effectively diagnosed benign and malignant ovarian neoplasia [95.7% sensitivity, 82.6% specificity, 89.2% accuracy, and receiver operating characteristic (ROC) area under the curve of 0.94]. The other two panels, consisting of five and four candidate protein biomarkers each, effectively distinguished between benign and malignant ovarian neoplasia and were therefore referred to as validation biomarker panel I (81.5% sensitivity, 94.9% specificity, 88.2% accuracy, and ROC = 0.94) and validation biomarker panel II (72.8% sensitivity, 94.9% specificity, 83.9% accuracy, and ROC = 0.90). The three ovarian cancer biomarker protein panels correctly diagnosed 41 of the 44 blinded test samples: 21 of 22 malignant ovarian neoplasias [10 of 11 early-stage ovarian cancer (I/II) and 11 of 11 advanced-stage ovarian cancer (III/IV)], 6 of 6 low malignant potential, 5 of the 6 benign tumors, and 9 of 10 normal patient samples. In conclusion, we have discovered three ovarian cancer biomarker protein panels that, when used together, effectively distinguished serum samples from healthy controls and patients with either benign or malignant ovarian neoplasia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., & Chan, D. W. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1296 · Cited by 893
Trends in Cancer Incidence, Survival and Mortality
Estève, J., & Coleman, M. (2009) · Husband and Reznek's Imaging in Oncology, Third Edition · doi:10.3109/9780415874984-2 · Cited by 761
Welsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., & Hampton, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1176 · Cited by 654
Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
Xu, Y. (1998) · JAMA · doi:10.1001/jama.280.8.719 · Cited by 637
The SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification
Issaq, H. J., Veenstra, T. D., Conrads, T. P., & Felschow, D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6678 · Cited by 538
Large-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum
Welsh, J. B., Sapinoso, L. M., Kern, S. G., Brown, D. A., Liu, T., Bauskin, A. R., Ward, R. L., Hawkins, N. J., Quinn, D. I., Russell, P. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530278100 · Cited by 503
Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
Kim, J.-H. (2002) · JAMA · doi:10.1001/jama.287.13.1671 · Cited by 480
Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K., Kondylis, F. I., Gong, L., Nasim, S., & Wright Jr., G. L. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64100-4 · Cited by 409
CA 125: The past and the Future
Bast, R. C., Xu, F.-J., Yu, Y.-H., Barnhill, S., Zhang, Z., & Mills, G. B. (1998) · The International Journal of Biological Markers · doi:10.1177/172460089801300402 · Cited by 397
Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G. E., Hellström, K. E., & Hellström, I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11531 · Cited by 344
Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology
Mok, S. C., Chao, J., Skates, S., Wong, K.-K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., & Cramer, D. W. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1458 · Cited by 320
Coordinately up-regulated genes in ovarian cancer.
Hough, C. D., Cho, K. R., Zonderman, A. B., Schwartz, D. R., & Morin, P. J. (2001) · PubMed · Cited by 315
Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L. A., Kohn, E. C., & Petricoin, E. F. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200201)2:1<76::aid-prot76>3.0.co;2-o · Cited by 290
CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival
Kristiansen, G., Denkert, C., Schlüns, K., Dahl, E., Pilarsky, C., & Hauptmann, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64398-2 · Cited by 261
Jr, G. W., Cazares, L., Leung, S., Nasim, S., Adam, B., Yip, T., Schellhammer, P., Gong, L., & Vlahou, A. (1999) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500384 · Cited by 260
Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M., de Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G. M., Stenman, U.-H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.022 · Cited by 234
Proteomic Approaches to Tumor Marker Discovery
Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I.-M., Pham, T., Fung, E. T., Sokoll, L. J., & Chan, D. W. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-1518-pattmd · Cited by 219
Identification of tumor antigens in renal cell carcinoma by serological proteome analysis
Klade, C. S., Voss, T., Krystek, E., Ahorn, H., Zatloukal, K., Pummer, K., & Adolf, G. R. (2001) · PROTEOMICS · doi:10.1002/1615-9861(200107)1:7<890::aid-prot890>3.0.co;2-z · Cited by 213
Cohen, L. S., Escobar, P. F., Scharm, C., Glimco, B., & Fishman, D. A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6253 · Cited by 203
Protein biochips for differential profiling
Fung, E. T., Thulasiraman, V., Weinberger, S. R., & Dalmasso, E. A. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00167-1 · Cited by 195
Luo, L., Katsaros, D., Scorilas, A., Fracchioli, S., Bellino, R., van Gramberen, M., de Bruijn, H., Alfthan, H., Stenman, U., Massobrio, M., et al. (2003) · PubMed · Cited by 153
Early Detection of Ovarian Cancer: Promise and Reality
Bast, R. C., Urban, N. D., Shridhar, V., Smith, D., Zhang, Z., Skates, S. J., Lu, K. H., Liu, J., Fishman, D. A., & Mills, G. B. (2002) · Cancer treatment and research · doi:10.1007/978-1-4757-3587-1_3 · Cited by 143
Martoglio, A.-M., Tom, B. D. M., Starkey, M. P., Corps, A. N., Jones, D. S., & Smith, S. K. (2000) · Molecular Medicine · doi:10.1007/bf03402191 · Cited by 131
van Haaften‐Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L. J., de Bruijn, H. W. A., van der Zee, A. G. J., Bast, R. C., & Hacker, N. F. (2001) · Cancer · doi:10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>3.0.co;2-5 · Cited by 122
Recent developments in ovarian cancer screening
Menon, U., & Jacobs, I. J. (2000) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200002000-00007 · Cited by 121
Wong, K., Cheng, R. S., & Mok, S. C. (2001) · BioTechniques · doi:10.2144/01303dd05 · Cited by 88
Mills, G. B., Bast, R. C., & Srivastava, S. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1437 · Cited by 71
Sedlaczek, P., Frydecka, I., Gabryś, M. S., van Dalen, A., EINARSSON, R., & Harlozinska, A. (2002) · Cancer · doi:10.1002/cncr.10917 · Cited by 69
Expression and Potential Role of Fas-Associated Phosphatase-1 in Ovarian Cancer
Meinhold-Heerlein, I. M., Stenner, F., Liewen, H., Kitada, S., Krajewska, M., Krajewski, S., Zapata, J. M., Monks, A. P., Scudiero, D. A., Bauknecht, T., et al. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64084-9 · Cited by 69
Fishman, D. A., & Bozorgi, K. (2002) · Springer eBooks · doi:10.1007/978-1-4757-3587-1_1 · Cited by 54
A rapid protein profiling system that speeds study of cancer and other diseases.
Rb, R., & M, M. E. (2001) · PubMed · Cited by 48
Gene expression profiling diagnosis through DNA molecular computation
Mills, A. P. (2002) · Trends in biotechnology · doi:10.1016/s0167-7799(01)01915-1 · Cited by 16
Cited by
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool
Diamandis, E. P. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400007-mcp200 · Cited by 631
Human body fluid proteome analysis
Hu, S., Loo, J. A., & Wong, D. T. (2006) · PROTEOMICS · doi:10.1002/pmic.200600284 · Cited by 533
Serum protein markers for early detection of ovarian cancer
Mor, G., Visintin, I., Lai, Y., Zhao, H., Schwartz, P., Rutherford, T., Yue, L., Bray-Ward, P., & Ward, D. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502178102 · Cited by 482
Electrical biosensors and the label free detection of protein disease biomarkers
Luo, X., & Davis, J. J. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60077g · Cited by 460
Metadata
- Authors
- Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F., Luong, M. N., Luong, S. A., Reddy, S. T., & Farias-Eisner, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-10
- Volume
- 100
- Issue
- 21
- Pages
- 12343-12348
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1987266144
- Cited by
- 276
- References
- 35
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.